Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2015, Vol. 20 ›› Issue (3): 269-273.

Previous Articles     Next Articles

Therapeutic effect of VEGF receptor inhibitor SU5614 in a murine model of toluene diisocyanate induced asthma

JIANG Ai-ying1, YU Ren-zhi1, LV Yu-feng1, LUO Hai-long2   

  1. 1Department of Respiratory Medicine, 2Department of Neurology, Hongqi Hospital of Mudanjiang Medical University,Mudanjiang 157011,Heilongjiang,China
  • Received:2014-06-07 Revised:2014-08-31 Published:2015-04-08

Abstract: AIM: To discuss the therapeutic effect of vascular endothelial growth factor (VEGF) receptor inhibitor SU5614 in a murine model of toluene diisocynate(TDI) induced asthma.METHODS: BALB/C mice were randomly divided into three groups: the control group, the model group and the SU5614 group.Using the TDI induced asthma in mice, the effect of SU5614 was evaluated on expression of VEGF in bronchoalveolar lavage fluid(BALF),pathological changes of lung tissue,determination of airway responsiveness to methacholine and measurement of plasma exudation.RESULTS: Immune cytological analysis showed that expression of VEGF in BALF was significantly increased in model group, but significantly decreased in the SU5614 group. The airway inflammation of lung tissue was expressed obviously in model group, but significantly reduced in the SU5614 group.The airway responsiveness increased in model group, while in the SU5614 group it was significantly reduced (P<0.05).Plasma exudation was significantly increased in model group, but significantly decreased in the SU5614 group (P<0.05).CONCLUSION: SU5614 not only inhibit VEGF activity in BALF,but also inhibit the migration of inflammatory cells, reduce airway inflammation and plasma exudation.

Key words: asthma, vascular endothelial growth factor, toluene diisocyanate, vascular endothelial growth factor receptor inhibitor, SU5614

CLC Number: